Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jan 11, 2025 3:23pm
78 Views
Post# 36399557

RE:RE:RE:JP Morgan healthcare conference

RE:RE:RE:JP Morgan healthcare conferenceBlockage of PI3K/Akt activation increases reovirus synthesis and viral yield, which results in enhnaced reovirus infection and the activation of an interferon (IFN)-stimulated response (a pro-inflammatory, cytokine activated response that results in the activation of the innate immune system) - thus turning "cold' tumors (like breast and pancreatic cancer) into 'hot' tumors.

Furthermore, ONCY's pelareorep is able to remodel a hostile tumor microenvironment (TME), which presents as a major obstacle to infilitrating T-lymphocytes by suppressing their function, into a TME with expanded T-cells that overcome T-cell dysfunction and T-cell exhaustion. Such a remodeled TME results in T-cells being trafficked  towards the cancer cell surface, and by so doing, turning a cold tumor into a  "hot" tumor, which then becomes ready for the sequential addition of an immune checkpoint inhibitor, as part of an immunochemotherapy combination  of drugs for effective the treatment of various. cancers, like breast, pancreatic, anal and GI cancers.
<< Previous
Bullboard Posts
Next >>